SecBot SecBot
DEFA14A ·Filed Apr 14, 2026

AVNS

AVANOS MEDICAL, INC.
NEUTRAL
Impact 4/10
Horizonweeks Processed7mo ago SEC0001104659-26-043093
Proxy solicitation materials
Actionable Insight • Neutral

Traders should monitor for further merger-related disclosures, including revised proxy materials and a rescheduled shareholder vote. The postponement suggests the merger process is active but may require additional regulatory or procedural steps.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$24.63
T+0 close · Apr 14, 2026 · via day close
Latest settled
+1.26%
T+60 · $24.94
Vs SPY
−7.26%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 14 $24.63entry
  2. T+1 · 7mo ago +0.37%α −0.41% · $24.72
  3. T+5 · 7mo ago +0.04%α −1.35% · $24.64
  4. T+20 · 6mo ago +0.73%α −5.56% · $24.81
  5. T+60 · 4mo ago +1.26%α −7.26% · $24.94
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Avanos Medical has postponed its 2026 Annual Meeting of Stockholders, originally set for April 21, 2026, due to its pending merger. This filing serves as definitive additional proxy materials disclosing the postponement.

Key Financial Metrics

Meeting
2026-04-21

Key Facts

  • Avanos Medical, Inc. (AVNS) has postponed its 2026 Annual Meeting of Stockholders.
  • The meeting was originally scheduled for April 21, 2026, and is being delayed due to a pending merger.
  • This DEFA14A filing is definitive additional materials related to the postponement.
  • The company filed the notice on April 14, 2026.

Financial Impact

No direct financial impact disclosed; postponement is procedural in light of merger.

meeting dategovernance timeline

Risk Factors

  • Merger delays or regulatory hurdles could extend timeline.
  • Integration risks or deal termination could impact shareholder value.

Market Snapshot

Exchange
NYSE
Sector
Orthopedic, Prosthetic & Surgical Appliances & Supplies

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001104659-26-043093
Document: 0001104659-26-043093-index-headers.html0001104659-26-043093
Document: 0001104659-26-043093-index.html0001104659-26-043093
Document: 0001104659-26-043093.txt0001104659-26-043093

Track record

7 reports on AVNS

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +1.13% at T+60 after the Apr 23, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Jul 27, 202616w ago 25-NSE Neutral 5/10 Entry $24.99 No price data
  2. Jul 2, 202619w ago 8-K / DEFA14A Bullish 7/10 Entry $24.93 to $24.94 ▲ +0.04% −0.89% vs SPY
  3. Jun 10, 202622w ago DEFM14A Bullish 8/10 Entry $24.98 to $24.87 ▼ −0.44% −0.87% vs SPY
  4. May 5, 202627w ago DEFA14A Neutral 5/10 Entry $24.72 to $24.73 ▲ +0.04% −1.09% vs SPY
  5. Apr 23, 202629w ago DEFA14A Bullish 8/10 Entry $24.71 to $24.65 ▼ −0.24% −1.72% vs SPY
  6. Apr 14, 202630w ago DEFA14A Neutral 4/10 Viewing Entry $24.63 to $24.64 ▲ +0.04% −1.35% vs SPY
  7. Feb 26, 202637w ago 8-K Neutral 5/10 Entry $14.49 to $13.79 ▼ −4.83% −3.70% vs SPY
Showing 7 of 7

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 14, 2026